iProgen develops next‑generation antibody‑drug conjugates (ADCs) for non‑oncology therapeutics, leveraging its proprietary Smart Antibodies™ platform to deliver advanced payloads such as oligonucleotides, PROTACs, and peptides. By combining engineered antibody delivery with novel payload chemistries, the company aims to expand the therapeutic reach of ADCs beyond cancer, partnering with global research leaders to accelerate development.
Funding
Funding not disclosed
Founders
Product
Problem
Current antibody‑drug conjugate (ADC) platforms are primarily designed for oncology, limiting the ability to deliver therapeutic payloads such as oligonucleotides, PROTACs, or peptides to non‑cancer targets. This restricts treatment options for a wide range of diseases where precise, targeted delivery is needed.
Solution
iProgen applies its proprietary Smart Antibodies™ technology to create next‑generation ADCs that can carry diverse, non‑oncology payloads. The platform enables site‑specific conjugation and controlled release of advanced therapeutics, improving target specificity and reducing off‑target effects. By integrating oligonucleotides, PROTACs, and peptide drugs into the ADC format, iProgen expands the therapeutic reach of antibody‑mediated delivery beyond cancer. The company collaborates with global research partners to accelerate discovery, preclinical development, and clinical translation of these novel ADC candidates.
Target Audience
Primary customers are pharmaceutical and biotech companies developing therapies for non‑cancer indications, as well as academic research groups seeking advanced ADC platforms for target validation.
Features
- Smart Antibodies™ platform provides site‑specific, high‑precision conjugation for consistent payload attachment
- Compatibility with a broad range of payload classes, including oligonucleotides, PROTACs, and therapeutic peptides
- Engineered release mechanisms that ensure payload activation at the intended disease site while minimizing systemic exposure
- Scalable ADC manufacturing processes optimized for non‑oncology indications
- Collaborative partnership model that leverages external expertise to fast‑track candidate validation and clinical development